Fibrocell Science, Inc. FCSC Cash Flow

Fibrocell science, inc. (FCSC)

CashFlow / TTM

Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net Income (Loss) Attributable to Parent
-773	3,595	-11,065	-10,300	-5,754	-3,010	-14,134	-16,240	-22,634	-24,818	-18,892	-15,292	-29,449	-28,671	-27,335	-34,453	-20,174	-24,665	-20,166	-25,650	0	0	0	-	-	-	-	-12,687	0	0	0	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Stock-based compensation expense
444	495	509	526	521	519	500	322	511	871	1,339	1,933	2,104	2,119	2,343	2,038	1,784	1,544	1,176	1,239	1,227	1,680	1,280	1,150	1,295	851	1,090	1,224	1,117	1,079	2,155	2,900	0	0	0
Stock issued for supplemental stock issuance agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liability revaluation income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,930	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Warrant Revaluation Income (Expense)
0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant revaluation and other finance (income) expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0
Warrant income (expense)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Unrealized Gain (Loss) on Derivatives
-3,200	438	1,900	1,700	-1,394	-1,769	-1,195	-1,407	76	79	-774	-462	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-23	0	0	0	-	-	-	0
Deferred tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,500	0	0	0	-	-	-	-
Loss on disposal or impairment of property and equipment
-	-	-	-	-	-	-	-40	-45	3,861	-99	-69	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization of long lived assets
341	358	376	392	404	402	394	384	370	357	438	564	689	812	844	767	764	777	801	883	843	859	859	863	910	885	856	821	686	537	346	158	0	0	0
Recovery of doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-12	-12	-16	-15	-5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on write-down of inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-44	-41	-46	0	0	0
Provision for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	14	10	18	0	0	0
Amortization of debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	146	0	0	0	-	-	-	-
Decrease (increase) in operating assets:
Foreign exchange gain on substantial liquidation of foreign entity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-12	-12	-19	-18	-9	-10	-16	-48	-12	-42	-62	26	-54	-45	37	5	60	96	40	79	4	0	0	0
Other receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	3	1	0	0	0
Inventory
-	-	-	-	-	-	-	-	-	-	-	-126	-566	-224	-69	-89	-44	8	38	-26	0	0	0	-	-	-	-	477	235	268	264	-38	0	0	0
Prepaid expenses and other current assets
955	356	732	-380	-9	14	-79	-28	1	-140	-446	-796	-268	-214	-133	-35	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	196	-954	211	534	437	0	0	0
Other assets
-	-	-89	-	-	-	-48	-26	-3	20	69	65	64	64	30	0	0	0	-142	-214	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Increase (decrease) in operating liabilities:
Accounts payable
816	410	1,013	-24	195	-72	147	69	205	56	-532	-139	-1,224	-1,178	-69	-114	1,737	1,586	1,283	-1,065	-1,345	-1,004	-1,572	807	-532	469	301	-966	663	-85	415	803	0	0	0
Related party payable
9	3,539	-321	-2,203	-1,668	-1,402	-1,135	1,361	1,390	754	431	-9,778	-1,094	261	-859	9,719	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses, deferred rent
795	270	718	263	-41	360	255	-342	-685	-472	137	-214	340	-476	-1,111	641	-551	287	577	894	908	1,364	1,201	188	960	-117	96	407	0	0	0	-	-	-	-
Accrued lease liabilities - operating lease
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest payable
792	785	778	771	762	756	749	742	737	596	411	228	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued expenses and other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-457	-473	-92	-126	41	-6	220	439	268	347	130	4	9	-4	19	46	83	122	130	84	55	0	0	0
Net Cash Provided by (Used in) Operating Activities
-9,768	-5,824	-11,039	-12,700	-14,375	-15,530	-17,044	-17,037	-16,673	-17,520	-18,081	-29,390	-33,222	-34,172	-35,931	-24,106	-23,264	-22,797	-20,581	-22,296	-19,548	-19,944	-20,969	-20,075	-23,357	-21,670	-21,325	-22,575	-19,815	-21,555	-19,991	-16,837	0	0	0
Cash flows from investing activities:
Purchase of property and equipment
349	168	138	164	240	273	381	433	414	353	282	253	250	303	221	271	143	142	271	242	505	449	339	360	182	256	372	493	1,256	1,228	1,773	1,570	0	0	0
Net cash used in investing activities
-349	-168	-138	-164	-240	-273	-381	-433	-414	-352	-281	-252	-223	-277	-195	-245	-143	-142	-271	-242	-505	-449	-339	-360	-182	746	630	509	-254	-1,228	-1,773	-1,570	0	0	0
Cash flows from financing activities:
Proceeds from 2017 Series A Preferred Stock Offering, (net of offering costs of $377)
-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of deferred offering costs
37	22	22	444	444	444	444	0	-92	-67	-8	42	134	109	50	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from conversion of pre-funded warrants
-	-	0	-	-	-	24	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	255	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	2	2	3	5	3	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on insurance loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97	121	104	91	81	0	0	0
Dividends paid on preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	470	221	427	480	623	0	0	0
Proceeds from financing activity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
791	4,320	10,292	9,894	18,815	15,301	9,066	17,372	7,715	25,623	25,827	17,889	17,797	15,760	15,920	16,124	16,124	253	152	0	47,392	49,118	49,122	49,122	40,296	39,177	42,704	42,613	5,349	22,739	22,631	28,336	0	0	0
Effect of exchange rate changes on cash balances
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash balances
-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	3	0	0	0
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-98	-9,372	7,751	7,465	-11,753	-15,648	-18,689	-20,206	-8,227	-7,284	-22,686	-20,700	-22,538	27,340	28,726	27,815	28,687	16,757	18,252	22,008	20,547	-14,722	-48	867	9,931	0	0	0
Supplemental disclosures of cash flow information:
Property and equipment in accounts payable
67	114	22	9	72	55	49	29	53	37	55	57	13	57	26	11	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs in accounts payable and accrued expenses
-	0	52	-	-	544	181	444	-18	12	245	23	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reduction of warrant liability upon cashless exercise of warrants
-	-	-	-	-	-	-	41	41	41	41	0	0	82	82	82	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividend paid in-kind to preferred stockholders
346	342	339	336	332	329	326	264	182	100	20	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock, Deemed Dividend
571	551	532	513	495	476	486	4,099	3,981	3,870	3,734	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-